Patent classifications
A61P35/02
Purine diones as Wnt pathway modulators
The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.
Anti-MIC antibodies and methods of use
The invention provides anti-MIC antibodies and methods of using the same.
Amide compounds as kinase inhibitors, compositions and methods of treatment
The present disclosure relates to certain amides and heterocyclic compounds and uses of these amides and heterocyclic compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graft versus host disease (GVHD), inflammation, cardiovascular disorders, central nervous system disorders, and neoplastic disorders.
Amide compounds as kinase inhibitors, compositions and methods of treatment
The present disclosure relates to certain amides and heterocyclic compounds and uses of these amides and heterocyclic compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graft versus host disease (GVHD), inflammation, cardiovascular disorders, central nervous system disorders, and neoplastic disorders.
Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
Provided herein is a combination product comprising a Bcl-2 inhibitor, an anti-CD20 antibody and/or bendamustine or a combination product comprising a Bcl-2 inhibitor and CHOP, the combination product provides a use of the combination product for prevention and/or treatment of a disease (e.g., cancer, rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis).
Methods for improved protection and delivery of aminothiols and analogs thereof
In one aspect, the present application relates to an aminothiol-conjugate of formula (I): ##STR00001##
wherein ,
, R.sub.1, R.sub.2, R.sub.3, m, n, and p are as described above. The present invention also relates to a method of treating a subject in need of aminothiol therapy using an aminothiol-conjugate of formula (I).
Methods for improved protection and delivery of aminothiols and analogs thereof
In one aspect, the present application relates to an aminothiol-conjugate of formula (I): ##STR00001##
wherein ,
, R.sub.1, R.sub.2, R.sub.3, m, n, and p are as described above. The present invention also relates to a method of treating a subject in need of aminothiol therapy using an aminothiol-conjugate of formula (I).
METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH PI3 KINASE DELTA INHIBITORS
Provided are methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a PI3K (phosphatidylinositol-4,5-bis-phosphate 3-kinase) delta inhibitor.
TREATMENT FOR ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME
The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.
IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF
The present invention relates to an imidazoquinoline substituted phosphoric ester agonist, and a preparation therefor and an application thereof. Specifically, the compounds of the present invention have the structure shown in formula (I), wherein the definition of each group and substituent is as described in the description. Also disclosed in the present invention are a preparation method for the compound and use thereof as a TLR agonist.
##STR00001##